p53 mutation does not affect prognosis in ovarian epithelial malignancies
- 21 March 2001
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 194 (1) , 68-75
- https://doi.org/10.1002/path.857
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- INK4a/ARFLocus Alterations in Human Non-Hodgkin's Lymphomas Mainly Occur in Tumors with Wild-Type p53 GeneThe American Journal of Pathology, 2000
- Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndromeOncogene, 1998
- Quantification of p53 in Epithelial Ovarian CancerGynecologic Oncology, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- p53 Gene Mutation in Human Borderline Epithelial Ovarian TumorsJNCI Journal of the National Cancer Institute, 1994
- P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significanceEuropean Journal Of Cancer, 1994
- p53, guardian of the genomeNature, 1992
- Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6Nature, 1991
- Adjuvant Therapy in Stage I and Stage II Epithelial Ovarian CancerNew England Journal of Medicine, 1990